The potential of dopamine agonists in drug addiction

Bibliography

• BOWERS MB, MALISON RT, SEIBYL JP, KOSTEN TR: Plasma homovanillic acid and the dopamine transporter during cocaine withdrawal. Biol. Psychiatry(1998) 43(4):278–281.
   PubMed Web of Science ®Google Scholar
• MCDOUGLE CJ, PRICE LH, PALUMBO JM, KOSTEN TR, HENINGER GR, KLEBER HD: Dopaminergic responsivity during cocaine abstinence: a pilot study. Psychiatry Res. (1992) 43(1):77–85.
   PubMed Web of Science ®Google Scholar
• SWARTZ CM, BREEN K, LEONE F: Serum prolactin levels during extended cocaine abstinence. Am. Psychiatry (1990) 147(6)777–779.
   Google Scholar
• JOHANSON C-E, FISCHMAN MM: The pharmacology of cocaine related to its abuse. Pharmacol Rev (1989) 41:3–52.
   PubMed Web of Science ®Google Scholar
• KOOB GF: Neural mechanisms of drug reinforcement. Ann. NY Acad. Sci. (1992) 654:171–191.
   PubMed Web of Science ®Google Scholar
• FUXE K, AGNATI LF, KALIA M, GOLDSTEIN M, ANDERSON K, HARFSTRAND A: Dopaminergic systems in the brain and pituitary. In: Basic and Clinical Aspects of Neurosdence. E Fluckiger, EE Muller, MO Thorner (Eds). Springer-Verlag, Berlin, Germany (1985):11–25.
   Google Scholar
• KOOB GF: Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sri. (1992) 13:177–184.
   PubMed Web of Science ®Google Scholar
• GUITART X, BEITNER-JOHNSON D, MARBY DW, KOSTEN TA, NESTLER EJ: Fischer and Lewis rat strains differ in basal levels of neurofilament proteins and their regulation by chronic morphine in the mesolimbic dopamine system. Synapse (1992) 12:242–253.
   PubMed Web of Science ®Google Scholar
• HAILE CN, HIROI N, NESTLER EJ, KOSTEN TA: Differential behavioral responses to cocaine are associated with dynamics of mesolimbic proteins in Lewis and Fischer 344 rats. Synapse (2001) 41:179–190.
   PubMed Web of Science ®Google Scholar
• MINABE Y, EMORI K, ASHBY CR: Significant differences in the activity of midbrain dopamine neurons between male Fischer 344 (F344) and Lewis rats: an in vivo electrophysiological study. Life Sri. (1995) 56:PL261–267.
   PubMed Web of Science ®Google Scholar
• CAMP DM, BROWMAN KE, ROBINSON TE: The effects of methamphetamine and cocaine on motor behavior and extracellular dopamine in the ventral striatum of Lewis versus Fischer 344 rats. Brain Res. (1994) 668:180–193.
   PubMed Web of Science ®Google Scholar
• STRECKER RE, EBERLE WF, ASHBY CR: Extracellular dopamine and its metabolites in the nucleus accumbens of Fischer and Lewis rats: basal levels and cocaine-induced changes. Life Sci. (1995) 56:PL135–141.
   PubMed Web of Science ®Google Scholar
• SCHUTZ CG, AMBROSIO E, SHIPPENBERG TS, ELMER GI, HEIDBREDER C: Morphine-induced locomotor activity and dopamine overflow in the nucleus accumbens in Lewis and Fischer 344 inbred rat strains: a comparative study. In: Monitoring Molecules M Neuroscience. Proceedings of the 6th International Conference on ha Vivo Methods. A Louilot, T Durkin, U Spampinato, M Cador (Eds). (1994).
   Google Scholar
• FLORES G, WOOD GK, BARBEAU D, QUIRION R, SRIVASTAVA LK: Lewis and Fischer rats: a comparison of dopamine transporter and receptors levels. Brain Res. (1998) 814:34–40.
   PubMed Web of Science ®Google Scholar
• HAILE CN, KOSTEN TA: Differential effects of D1- and D2-like compounds on cocaine self-administration in Lewis and Fischer 344 inbred rats. Pharmacol Exp. Ther. (2001) 299:509–518.
   PubMed Web of Science ®Google Scholar
• COWEN MS, LAWRENCE AJ: The role of opioid-dopamine interactions in the induction and maintenance of ethanol consumption. Frog. Neuropsychopharmacol Biol. Psychiatry (1999) 23(7):1171–1212.
   PubMed Web of Science ®Google Scholar
• WEISS F, LORANG MT, BLOOM FE, KOOB GF: Oral alcohol self-administration stimulates dopamine release in the rat nucleus accumbens: genetic and motivational determinants. Pharmacol Exp. Ther. (1993) 267:250–258.
   PubMed Web of Science ®Google Scholar
• GEORGE SR, FAN T, NG GYK, JUNG SY, O'DOWD BE NARANJO CA: Low endogenous dopamine function in brain predisposes to high alcohol preference and consumption: reversal by increasing synaptic dopamine. Pharmacol Exp. Ther. (1995) 273:373–379.
   PubMed Web of Science ®Google Scholar
• NG GY, GEORGE SR: Dopamine receptoragonist reduces ethanol self-administration in the ethanol-preferring C57BL/6J inbred mouse. Eur. Pharmacol (1994) 269(3):365–374.
   PubMed Web of Science ®Google Scholar
• LAWFORD BR, YOUNG RM, ROWELL JA et al.: Bromocriptine in the treatment of alcoholics with the D2 dopamine receptor Al allele. Nat. Med. (1995) 1(4):337–341.
   PubMed Web of Science ®Google Scholar
• •Suggests role of genetic factors for selecting patients who may respond to DA agonist therapy.
   Google Scholar
• BORG V, WEINHOLDT T: Bromocriptinein the treatment of the alcohol-withdrawal syndrome. Acta Psychiam. Scand. (1982) 65(2):101–111.
   PubMed Web of Science ®Google Scholar
• BURROUGHS AK, MORGAN MY, SHERLOCK S: Double-blind controlled trial of bromocriptine, chlordiazepoxide and chlormethiazole for alcohol withdrawal symptoms. A/coho/A/cohoL (1985) 20:263–271.
   Google Scholar
• BORG V: Bromocriptine in the preventionof alcohol abuse. Acta Psychiatr. Scam/. (1983) 68(2):100–110.
   PubMed Web of Science ®Google Scholar
• DONGIER M, VACHON L, SCHWARTZ G: Bromocriptine in the treatment of alcohol dependence. Alcohol Gin. Exp. Res. (1991) 15:970–977.
   Web of Science ®Google Scholar
• NARANJO CA, DONGIER M, BREMNER KE: Long-acting injectable bromocriptine does not reduce relapse in alcoholics. Addiction (1997) 92(8):969–978.
   PubMed Web of Science ®Google Scholar
• ••The best controlled study of bromocriptinefor alcoholism showing no efficacy for reducing alcohol use or related psychological symptoms.
   Google Scholar
• POWELL BJ, CAMPBELL JL, LANDON JF et al.: A double-blind, placebo-controlled study of nortriptyline and bromocriptine in male alcoholics subtyped by comorbid psychiatric disorders. Alcohol. Clin. Exp. Res. (1995) 19(2):462–468.
   PubMed Web of Science ®Google Scholar
• MALCOLM R, KAJDASZ DK, HERRON J, ANTON RF, BRADY KT: A double-blind, placebo-controlled outpatient trial of pergolide for cocaine dependence. Drug Alcohol Depend. (2000) 60(2):161–168.
   PubMed Web of Science ®Google Scholar
• ••Largest study involving both alcohol- andcocaine-dependent patients showing no efficacy for pergolide, a direct DA agonist.
   Google Scholar
• SCHOTTENFELD RS, O'MALLEY SS, SMITH L, ROUNSAVILLE BJ, JAFFE JH: Limitation and potential hazards of MA0I's for the treatment of depressive symptoms in abstinent alcoholics. Am. Drug Alcohol Abuse (1989) 15(3):339–344.
   PubMed Web of Science ®Google Scholar
• YU YL, FISHER H, SEKOWSKI A, WAGNER GC: Amphetamine and fenfluramine suppress ethanol intake in ethanol-dependent rats. Alcohol (1997) 14(1):45–48.
   PubMed Web of Science ®Google Scholar
• GAWIN FH, ELLINWOOD EH: Cocaine and other stimulants: actions, abuse and treatment. N Engl. I Med. (1988) 318(18):1173–1181.
   PubMed Web of Science ®Google Scholar
• KUMOR K, SHERER M, JAFFE J: Effects of bromocriptine pretreatment on subjective and physiological responses to IV cocaine. Pharmacol Biochem. Behav. (1989) 33:829–837.
   PubMed Web of Science ®Google Scholar
• TENNANT FS, SAGHERIAN A: Double-blind comparison of amantadine and bromocriptine for ambulatory withdrawal from cocaine dependence. Arch. Intern. Med. (1987) 147:109–112.
   PubMed Web of Science ®Google Scholar
• MOSCOVITZ H, BROOKOFF D, NELSON L: A randomized trial of bromocriptine for cocaine users presenting to the emergency department. J. Gen. Intern. Med. (1993) 8:1–4.
   PubMed Web of Science ®Google Scholar
• HANEY M, FOLTIN RW, FISCHMAN MW: Effects of pergolide on intravenous cocaine self-administration in men and women. Psychopharmacology (1998) 137(1):15–24.
   PubMed Web of Science ®Google Scholar
• MALCOLM R, MOORE JW, KAJDASZ DK: Pergolide mesylate: adverse events occurring in the treatment of cocaine dependence. Am. I Addictions (1997) 6(2):117–123.
   PubMed Web of Science ®Google Scholar
• HANEY M, COLLINS ED, WARD AS, FOLTIN RW, FISCHMAN MW: Effect of a selective dopamine D1 agonist (ABT-431) on smoked cocaine self-administration in humans. Psychopharmacology (1999) 143(1):102–110.
   PubMed Web of Science ®Google Scholar
• PILLA M, PERACHON S, SAUTEL F et al.: Selective inhibition of cocaine seeking behavior by a partial dopamine D3 receptor agonist. Nature (1999) 400:371–375.
   PubMed Web of Science ®Google Scholar
• •Animal study suggesting efficacy of a partial dopamine agonist at a new dopamine receptor subtype, the D3 receptor.
   Google Scholar
• GRABOWSKI J, ROACHE JD, SCHMITZ JM, RHOADES H, CRESON D, KORSZUN A: Replacement medication for cocaine dependence: methylphenidate. Clin. Psychopharmacol (1997) 17:485–488.
   PubMed Web of Science ®Google Scholar
• PRESTON KL, SULLIVAN JT, BERGER P, BIGELOW GE: Effects of cocaine alone and in combination with mazindol in human cocaine abusers. J. Pharmacol Exp. Ther. (1993) 267:296–307.
   PubMed Web of Science ®Google Scholar
• STINE SM, KRYSTAL JH, KOSTEN TR, CHARNEY DS: Mazindol treatment for cocaine dependence. Drug Alcohol Depend. (1995) 39:245–252.
   PubMed Web of Science ®Google Scholar
• •Placebo-controlled study showing no efficacy for mazindol in cocaine dependence.
   Google Scholar
• MARGOLIN A, AVANTS SK, KOSTEN TR: Mazindol for relapse prevention to cocaine abuse in methadone-maintained patients. Am. J. Drug Alcohol Abuse(1995) 21(4):469–481.
   PubMed Web of Science ®Google Scholar
• SHOLAR MB, LUKAS SE, KOURI E et al.: Acute and chronic amantadine pre-treatment attenuates some of cocaine's effect in human subjects. NIDA Res. Monogr: (1994) 141: 431.
   Google Scholar
• ALTERMAN Al, DROBA M, ANTELO RE et al.: Amantadine may facilitate detoxification of cocaine addicts. Drug Alcohol Depend. (1992) 31:19–29.
   PubMed Web of Science ®Google Scholar
• •Suggested efficacy of this indirect DA agonist for cocaine abusers, but other studies have shown no efficacy for this compound in this group.
   Google Scholar
• HABERNY KA, WALSH SL, GINN DH et al.: Absence of acute cocaine interactions with the MAO-B inhibitor selegiline. Drug Alcohol Depend. (1995) 39(1):55–62.
   PubMed Web of Science ®Google Scholar
• BARTZOKIS G, BECKSON M, NEWTON T et al.: Selegiline effects on cocaine-induced changes in medial temporal lobe metabolism and subjective ratings of euphoria. Neuropsychopharmacology (1999) 20(6):582–590.
   PubMed Web of Science ®Google Scholar
• MCCANCE EF, KOSTEN TR, JATLOW P: Disulfiram effects on acute cocaine administration. Drug Alcohol Depend. (1998) 52(1):27–39.
   PubMed Web of Science ®Google Scholar
• CARROLL KM, NICH C, BALL SA, MCCANCE E, ROUNSAVILLE BJ: Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction (1998) 93(5):713–727.
   PubMed Web of Science ®Google Scholar
• ••Disulfirarn may act as an indirect DAagonist by blocking conversion of DA to NA and this study shows efficacy of disuffirarn in reducing cocaine abuse.
   Google Scholar
• SLEMMER JE, MARTIN BR, DAMAJ MI: Bupropion is a nicotinic antagonist. Pharm. Exp. Ther: (2000) 295:321–327.
   PubMed Web of Science ®Google Scholar
• HALL SM, REUS VI, MUNOZ RF et al.: Nortriptyline and cognitive-behavioral therapy in the treatment of cigarette smoking. Arch. Gen. Psychiatry (1998) 55:683–690.
   PubMed Web of Science ®Google Scholar
• MAHMOOD, I: Clinical pharmacokineticsand pharmacodynamics of selegiline. Pharmacokinet. (1997) 33:91–102.
   PubMed Web of Science ®Google Scholar
• HEINONEN EH, SAVIJARVI M, KOTILA M, HAJBA A, SCHEININ M: Effects of monoamine inhibition by selegiline on concentrations of noradrenaline and monoamine metabolites in CSF of patients with Alzheimer's disease. J. Neural. Transm. (1993) 5:193–202.
   Web of Science ®Google Scholar
• GEORGE TP, VERRICO CD, ROTH RH: Effects of repeated nicotine pre-treatment on mesoprefontal dopaminergic and behavioral responses to acute footshock stress. Brant Res. (1998) 801:36–49.
   PubMed Web of Science ®Google Scholar
• FUNG YK, SCHMID MJ, ANDERSON TM, LAU Y-S: Effects of nicotine withdrawal on central dopaminergic systems. Pharmacol Biochem. Behav. (1996) 53:635–640.
   PubMed Web of Science ®Google Scholar
• HILDEBRAND BE, NOMIKOS GG, PANAGIS G, HERTEL P, SCHILSTROM B, SVENNSON TH: Reduced dopamine output in the nucleus accumbens but not in the medial prefrontal cortex in rats displaying a mecamylamine-precipitated nicotine withdrawal syndrome. Brain Res. (1998) 779:214–225.
   PubMed Web of Science ®Google Scholar
• WARD KD, GARVEY AJ, BLISS RE, SPARROW D, YOUNG JB, LANDSBERG L: Changes in urinary catecholamine excretion after smoking cessation. Pharmacol Biochem. Behav. (1991) 40:937–940.
   PubMed Web of Science ®Google Scholar
• WEST RJ, RUSSELL MAH, JARVIS MJ, PIZZEY T, KADAM B: Urinary adrenaline concentrations during 10 days of smoking abstinence. Psychopharmacol (1984) 84:141–142.
   Web of Science ®Google Scholar
• ELGEROT A: Psychological and physiological changes during tobacco abstinence in habitual smokers. J Clin. Psycho]. (1978) 34:759–764.
   Web of Science ®Google Scholar
• KUHN W, MULLER T: The clinical potential of Deprenyl in neurologic and psychiatric disorders. J. Near: Transm. (1996) 48 (Suppl.):85–93.
   Google Scholar
• YASAR S, GOLDBERG JP, GOLDBERG SR: Are metabolites of L-deprenyl (selegiline) useful or harmful?: indications from preclinical research. J. Near: Transm. (1996) 48 (Suppl.):61–73.
   Google Scholar
• NICKEL B, SZELENYI I, SCHULZE G: Evaluation of physical dependence liability of L-deprenyl (selegiline) in animals. Clin. Pharmacol Ther. (1994) 56:757–767.
   PubMed Web of Science ®Google Scholar
• GEORGE TP, VESSICCHIO JC, TERMINE A, JATLOW PI, KOSTEN TR, O'MALLEY SS: A preliminary trial of selegiline hydrochloride versus placebo for smoking cessation. Am. Psychiatry (2001): in submission.
   Google Scholar
• ••Study showing that this indirect DA agonistthat acts by inhibiting the breakdown of DA may improve smoking cessation.
   Google Scholar
• HUGHES JR, GOLDSTEIN MG, HURT RD, SHIFFMAN S: Recent advances in the pharmacotherapy of smoking. JAMA (1999) 281:72–76.
   PubMed Web of Science ®Google Scholar
• BRAUER LH, PAXTON DA, STOCK CT,ROSE JE: Selegiline and transdermalnicotine for smoking cessation. SRNT Abstract, 6th Annual Meeting, Arlington, VA, USA (2000).
   Google Scholar
• IMPERATO A, MULAS A, DI CHIARA G: Nicotine preferentially stimulates dopamine release in the limbic system of freely moving rats. Eur: J Pharmacol (1986) 90:468–470.
   Google Scholar
• FOWLER JS, VOLKOW ND, WANG G-J et al.: Inhibition of monoamine oxidase B in the brains of smokers. Nature (1996) 379:733–736.
   PubMed Web of Science ®Google Scholar
• FOWLER JS, VOLKOW ND, WANG G-J et al: Brain monoamine oxidase A inhibition in cigarette smokers. Proc. Natl. Acad. Sci. USA (1996) 93(24):14065–14069.
   PubMed Web of Science ®Google Scholar
• BERLIN I, SAID S, SPREUX-VAROQUAUX 0 et al: A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers. Clin. Pharmacol. Ther. (1995) 58(4):444–452.
   PubMed Web of Science ®Google Scholar
• •Another study supporting the use of MAO inhibition as a type of indirect DA agonism for smoking cessation.
   Google Scholar
• PULVIRENTI L, KOOB GF: Dopamine receptor agonists, partial agonists and psychostimulant addiction. Trends Pharmacol. Sci. (1994) 15:374–379.
   PubMed Web of Science ®Google Scholar
• BERGMAN J, FRANCE CP, HOLTZMAN SG, KATZ JL, KOEK W, STEPHENS DN: Agonist efficacy, drug dependence, and medications development: preclinical evaluation of opioid, dopaminergic, and GABAA -ergic ligands. Psychopharmacology (2000) 153:67–84.
   PubMed Web of Science ®Google Scholar
• ARIENS EJ: Affinity and intrinsic activity in the theory of competitive inhibition. Arch. hat. Pharmacodyn. Ther. (1954) 99:32–49.
   PubMedGoogle Scholar
• FURCHGOTT RF: The pharmacology of vascular smooth muscle. Adv. Drug Res. (1955) 3:21–56.
   Google Scholar
• WOOLVERTON WL, GOLDBERG LI, GINOS JZ: Intravenous self-administration of dopamine receptor agonists by rhesus monkeys. J Pharmacol. Exp. Ther. (1984) 230:678–683.
   PubMed Web of Science ®Google Scholar
• SELF DW, STEIN L: The D1 agonists SKF82958 and SKF 77434 are self-administered by rats. Brain Res. (1992) 582:349–352.
   PubMed Web of Science ®Google Scholar
• KOSTEN TA, KOSTEN TR: Pharmacological blocking agents for treating substance abuse. Nerv. Ment. Dis. (1991) 179:583–592.
   PubMed Web of Science ®Google Scholar
• VOLKOW ND, WANG GJ, FOWLER JS etal.: Decreased striatal dopaminergic responsivity in detoxified cocaine abusers. Nature (1997) 386:830–833.
   Google Scholar
• AMBROSIO E, GOLDBERG SR, ELMER GI: Behavior genetic investigation of the relationship between spontaneous locomotor activity and the acquisition of morphine self-administration behavior. Behav. Pharmacol. (1995) 6:229–237.
   PubMed Web of Science ®Google Scholar
• KOSTEN TA, MISERENDINO MJD, HAILE CN, DECAPRIO JL, JATLOW PI, NESTLER EJ: Acquisition and maintenance of intravenous cocaine self-administration in Lewis and Fischer inbred rat strains. Biafra Res. (1997) 778:418–429.
   Google Scholar
• KATZ JL, WITKIN JM: Selective effects ofthe D1 dopamine agonist, SKF 38393, on behavior maintained by cocaine injection in squirrel monkey. Psychopharmacology (1992) 109:241–244.
   PubMed Web of Science ®Google Scholar
• SPEALMAN RD, BERGMAN J, ROSENZWEIG-LIPSON S: Differential modulation of behavioral effects of cocaine in squirrel monkeys: involvement of dopamine receptor subtypes. Psychopharmacology(1997) 133:283–292.
   PubMed Web of Science ®Google Scholar
• TIDEY JW, BERGMAN J: Drug discrimination in methamphetamine-trained monkeys: agonist and antagonist effects of dopaminergic drugs. J. Pharmacol. Exp. Ther. (1998) 285:1163–1174.
   PubMed Web of Science ®Google Scholar
• LEFOLL B, SCHWARTZ JC, SOKOLOFF P: Dopamine D3 receptor agents as potential new medications for drug addiction. Eur. Psychiatry (2000) 15:140–146.
   PubMed Web of Science ®Google Scholar
• VOLKOW ND, LOGAN J, FOWLER JS et al: Association between age-related decline in brain dopamine activity and impairment in frontal and cingulate metabolism. Am. J. Psychiatry (2000) 157(1):75–80.
   PubMed Web of Science ®Google Scholar
• RICHTAND NM, WOODS SC, BERGE SP, STRAKOWSKI SM: D3 dopamine receptor, behavioral sensitization, and psychosis. Neurosci. Biobehav. Rev (2001) 25:427–443.
   PubMed Web of Science ®Google Scholar
• CAINE SB, KOOB GF: Modulation of cocaine self-administration in the rat through D3 dopamine receptors. Science (1993) 260: 1814-1816.
   Google Scholar
• CAINE SB, KOOB GF: Pretreatment with the dopamine agonist 7-0H-DPAT shifts the cocaine self-administration dose-effect function to the left under different schedules in the rat. Behav. Pharmacol. (1995) 6:333–347.
   PubMed Web of Science ®Google Scholar
• STALEY JK, MASH DC: Adaptive increase in D3 dopamine receptors in the brain reward circuits of human cocaine fatalities. J Neurosci. (1996) 16:6100–6106.
   PubMed Web of Science ®Google Scholar
• DUAX E, GORWOOD P, SAUTEL F et al: Homozygosity at the dopamine D3 receptor gene is associated with opioid dependence. Mol. Psychiatry(1998) 3:333–336.
   PubMed Web of Science ®Google Scholar
• GORWOOD P, LIMOSIN F, BATEL P, DUAUX E, GOUYA L, ADES J: The genetics of addiction: alcohol-dependence and D3 dopamine receptor gene. Pathol. Biol. (2001) 49:710–717.
   PubMed Web of Science ®Google Scholar